#Heart Failure #Acorai #CAPTURE-HF

Acorai's Non-Invasive Monitoring Solution: A Game Changer in Heart Failure Management

Acorai, a pioneering clinical-stage company, is revolutionizing heart failure management with a cutting-edge non-invasive technology designed to improve patient outcomes. Recently, at the Heart Failure Society of America’s (HFSA) Annual Scientific Meeting in Minneapolis, the company unveiled impressive topline results from its ambitious CAPTURE-HF study, which involved 1,600 patients across 20 global sites.

The CAPTURE-HF Study Overview

The CAPTURE-HF study aimed to evaluate the performance of Acorai's AI-driven, multi-sensor device against the gold standard of invasive right heart catheterization. Conducted in two phases, the study enrolled a diverse pool of patients, assessing the accuracy, safety, and usability of the device. The principal investigator, Dr. Andrew J. Sauer, Professor of Medicine at Saint Luke's Kansas City, highlighted the device's ability to estimate pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) with remarkable sensitivity and specificity.

Key Findings

The results presented were compelling:

• - Pulmonary Capillary Wedge Pressure (PCWP > 15 mmHg):

- AUC: 0.821
- Sensitivity: 86%
- Specificity: 53%
- Negative Predictive Value (NPV): 90%

• - Right Atrial Pressure (RAP > 10 mmHg):

- AUC: 0.852
- Sensitivity: 87%
- Specificity: 70%
- NPV: 97%

These results exhibit the device's high sensitivity and strong negative predictive values, making it an essential tool for healthcare providers in rapid emergency department triage and fluid management.

Importance for Clinicians

Dr. Sauer emphasized that the